Related Experiment Video
Updated: Jun 10, 2025

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Are nucleot(s)ide analogues a negative factor for HBsAg seroconversion in acute hepatitis B?
M F Keser1, M A Erdogan2, O Yıldırım2
1Battalgazi State Hospital, Internal Medicine Clinic, Malatya, Turkey.
Tenofovir disoproxil fumarate (TDF) therapy in acute hepatitis B may increase chronicity rates and reduce natural immunity development. Further research is needed to confirm these findings for antiviral treatment efficacy.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Acute hepatitis B (HBV) treatment efficacy varies, with some studies showing survival benefits from antivirals and others no effect.
- Tenofovir disoproxil fumarate (TDF) is an antiviral medication used in HBV treatment.
- HBsAg seroconversion is a key indicator of viral clearance and immune recovery.
Purpose of the Study:
- To evaluate the efficacy of tenofovir disoproxil fumarate (TDF) in acute hepatitis B patients.
- To assess the impact of TDF on HBsAg seroconversion rates in acute HBV infection.
Main Methods:
- Retrospective analysis of 126 patients with acute HBV infection.
- Evaluation of demographic data, molecular, ELISA, and biochemistry tests.
- Comparison between patients treated with TDF and those without antiviral therapy.
Main Results:
- The rate of HBV chronicity was significantly higher in the TDF treatment group compared to the untreated group.
- The acquisition of protective anti-HBs antibodies was lower in patients receiving TDF (p<0.05).
Conclusions:
- TDF therapy for acute HBV infection might be associated with an increased risk of chronicity.
- Antiviral treatment with TDF may potentially impair the development of natural immunity against HBV.
- Further clinical studies are essential to elucidate the long-term effects and optimal use of TDF in acute hepatitis B.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
10:37Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
Related Concept Videos
Retrovirus Life Cycles
Viruses with RNA Genomes